{{위키데이터 속성 추적}}
{{과학자 정보
|이름=이호영
|그림=이호영 교수님 사진.png
|그림 크기=250px
|국적=[[대한민국]]
|분야=[[약학]]
|소속=[[서울대학교]] 약학대학 교수
|수상=신풍호월학술상(2017)<br>마크로젠 여성과학자상(2017)<br>3∙1문화상(2018)<br>한국 로레알-유네스코 여성과학자상 학술진흥상(2018)
}}

'''이호영'''([[1961년]]~)은 대한민국의 약학자로, 미국 MD 앤더슨 암센터 정교수를 거쳐 현재 [[서울대학교]] 약학대학에서 교수로 재직 중이다.

== 학력 ==
1984년 [[이화여자대학교]]에서 약학과 학사를 졸업하였고, 동 대학에서 1986년 석사학위를, 1992년 박사학위를 취득하였다. 

== 경력 ==
1992년부터 1995년까지 [[부산대학교]] 분자생물학과와 서울대학교 암연구소에서 박사후 연수과정을 거쳤고, 1995년 도미하여 1997년까지 미국 MD 앤더슨 암센터에서 박사후 연구원, 1997년부터 1999년까지 동 기관에서 Research Associate로 재직하였다. 1999년부터 2011년까지 미국 MD 앤더슨 암센터에서 조교수, 부교수를 거쳐 종신교수로 재직하였고, 2011년 3월부터 서울대학교 약학대학에 재직하고 있다. 2017년 [[한국과학기술원]]  한림원의 정회원으로 선출되었고, 현재 전문학술지인 Scientific Reports 및 Cancer Prevention Research의 editorial board 및 Cancer Research and Treatment의 associate editor로 활동하고 있다. 

== 수상 ==
2017년 신풍호월학술상<ref>{{웹 인용|url=http://www.monews.co.kr/news/articleView.html?idxno=101156|제목=서울대약대 이상국·이호영 교수, 신풍호월학술상 수상|날짜=2017-05-11|언어=ko|확인날짜=2020-05-26}}{{깨진 링크|url=http://www.monews.co.kr/news/articleView.html?idxno=101156 }}</ref> 및 마크로젠 여성과학자상<ref>{{웹 인용|url=https://www.yna.co.kr/view/AKR20170518084100017|제목='마크로젠 여성과학자상'에 서울대 이호영 교수|성=김잔디|날짜=2017-05-18|언어=ko|확인날짜=2020-05-26}}</ref>, 2018년 3∙1문화상<ref>{{웹 인용|url=https://www.yna.co.kr/view/AKR20180201081800005|제목=3·1문화상에 이승재·이호영·성영철 교수|성=박상현|날짜=2018-02-01|언어=ko|확인날짜=2020-05-26}}</ref> 및 [[한국 로레알-유네스코 여성과학자상]]<ref>{{웹 인용|url=https://www.yna.co.kr/view/AKR20180619047800030|제목=한국로레알-유네스코 여성과학자상 학술진흥상에 이호영 교수|성=김은경|날짜=2018-06-19|언어=ko|확인날짜=2020-05-26}}</ref> 학술진흥상을 수상하였다.

== 발표논문 ==
# Lee HY, Dohi DF, Kim YH, Walsh GL, Consoli U, Andreeff M, Dawson MI, Hong WK, Kurie JM (1998) “All-trans retinoic acid converts E2F into a transcriptional suppressor and inhibits the growth of normal human bronchial epithelial cells through a retinoic acid receptor- dependent signaling pathway” Journal of Clinical Investigation 101(5):1012-9. 
# Chun KH, Kosmeder JW, Sun S, Pezzuto JM, Lotan R, Hong WK, Lee HY (2003) “Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells”  Journal of the National Cancer Institute 95(4):291-302.
# Lee HY, Moon H, Chun KH, Chang YS, Hassan K, Ji L, Lotan R, Khuri FR, Hong WK (2004) “Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells” Journal of the National Cancer Institute 96(20):1536-48.
# Lee HY, Chang YS, Han JY, Liu DD, Lee JJ, Lotan R, Spitz MR, Hong WK (2005) “Effects of 9-cis-retinoic acid on the insulin-like growth factor axis in former smokers” Journal of Clinical Oncology 23(19):4439-49. 
# Han JY, Oh SH, Morgillo F, Myers JN, Kim E, Hong WK, Lee HY (2005) “Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer” Journal of the National Cancer Institute  97(17):1272-8.
# Lee HY, Oh SH, Woo JK, Kim WY, Van Pelt CS, Price RE, Cody D, Tran H, Pezzuto JM, Moriarty RM, Hong WK (2005) “Chemopreventive effects of deguelin, a novel Akt inhibitor, on tobacco-induced lung tumorigenesis” Journal of the National Cancer Institute 97(22):1695-9.
# Morgillo F, Woo JK, Kim ES, Hong WK, Lee HY (2006) “Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib” Cancer Research 66(20):10100-11.  
# Oh SH, Woo JK, Yazici YD, Myers JN, Kim WY, Jin Q, Hong SS, Park HJ, Suh YG, Kim KW, Hong WK, Lee HY (2007) “Structural basis for depletion of heat shock protein 90 client proteins by deguelin” Journal of the National Cancer Institute 99(12):949-61.
# Kim WY, Oh SH, Woo JK, Hong WK, Lee HY (2009) “Targeting heat shock protein 90 overrides the resistance of lung cancer cells by blocking radiation-induced stabilization of hypoxia-inducible factor-1alpha” Cancer Research 69(4):1624-32.
# Kim JH, Choi DS, Lee OH, Oh SH, Lippman SM, Lee HY (2011) “Antiangiogenic antitumor activities of IGFBP-3 are mediated by IGF-independent suppression of Erk1/2 activation and Egr-1-mediated transcriptional events” Blood 118(9):2622-31.
# William WN., Kim JS, Liu DD, Solis L, C. Behrens, Lee JJ, S. M. Lippman, Kim ES, Hong WK, Wistuba Il, Lee HY (2012) “The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival“ Annals of Oncology 23(1):78-85. 
# Shin DH, Lee HJ, Min HY, Choi SP, Lee MS, Lee JW, Johnson FM, Mehta K, Lippman SM, Glisson BS, Lee HY (2013) “Combating Resistance to Anti-IGFR Antibody by Targeting the Integrin β3-Src Pathway” Journal of the National Cancer Institute 105(20):1558-70.
# Min HY, Yun HJ, Lee JS, Lee HJ, Cho J, Jang HJ, Park SH, Liu D, Oh SH, Lee JJ, Wistuba II, Lee HY (2015) “Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancer” Molecular Cancer 14:113. 
# Lee JS, Kang JH, Boo HJ, Hwang SJ, Hong S, Lee SC, Park YJ, Chung TM, Yoon H, Lee SM, Kim BJ, Chung JK, Chung Y, William WN, Shin YK, Lee HJ, Oh SH, Lee HY (2015) “STAT3-mediated IGF-2 secretion in the tumor microenvironment elicits innate resistance to anti-IGF-1R antibody” Nature Communications 6:8499. 
# Lee SC, Min HY, Choi H, Bae SY, Park KH, Hyun SY, Lee HJ, Moon J, Park SH, Kim JY, An H, Park SJ, Seo JH, Lee S, Kim YM, Park HJ, Lee SK, Lee J, Lee J, Kim KW, Suh YG, Lee HY (2016) “Deguelin analogue SH-1242 inhibits Hsp90 activity and exerts potent anticancer efficacy with limited neurotoxicity” Cancer Research 76(3):686-99.
# Boo HJ, Min HY, Jang HJ, Yun HJ, Smith JK, Jin Q, Lee HJ, Liu D, Kweon HS, Behrens C, Lee JJ, Wistuba II, Lee E, Hong WK, Lee HY (2016) “The tobacco-specific carcinogen-operated calcium channel promotes lung tumorigenesis via IGF2 exocytosis in lung epithelial cells” Nature Communications 7:12961.
# Jang HJ, Boo HJ, Lee HJ, Min HY, Lee HY (2016) “Chronic stress facilitates lung tumorigenesis by promoting exocytosis of IGF2 in lung epithelial cells” Cancer Research 76(22):6607-19. 
# Min HY, Lee SC, Woo JK, Jung HJ, Park KH, Jeong HM, Hyun SY, Cho J, Lee W, Park JE, Kwon SJ, Lee HY, Ni X, Shin YK, Johnson FM, Duvic M, Lee HY (2017) “Essential role of DNA methyltransferase 1-mediated transcription of insulin-like growth factor 2 in resistance to histone deacetylase inhibitors” Clinical Cancer Research 23(5):1299-311.
# Lee HJ, Pham PC, Hyun SY, Baek B, Kim B, Kim Y, Min HY, Lee J, Lee HY (2018) “Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with minimal toxicity“ Molecular Cancer 17(1):50. 
# Cho J, Lee HJ, Hwang SJ, Min HY, Kang HN, Park AY, Hyun SY, Sim JY, Lee HJ, Jang HJ, Suh YA, Hong S, Shin YK, Kim HR, Lee HY (2019) “The interplay between slow-cycling, chemoresistant cancer cells and fibroblasts creates a proinflammatory niche for tumor progression” Cancer Research, in press.

== 각주 ==
<references />

{{전거 통제}}

[[분류:1961년 출생]]
[[분류:살아있는 사람]]
[[분류:대한민국의 생화학자]]
[[분류:약학자]]
[[분류:대한민국의 여자 과학자]]
[[분류:대한민국의 대학 교수]]
[[분류:이화여자대학교 동문]]